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Introduction 
Tumor necrosis factor (TNF) inhibitors are well 
known for their potential to trigger or induce 
dermatitis, including pompholyx or dyshidrotic 
eczema [1]. Even though new biologic therapies are 
emerging for the treatment of psoriasis, the 
knowledge about their impact on the pathogenesis 
of atopic dermatitis is limited. The IL17A antagonist, 
secukinumab, generally has a favorable side effect 
profile and is more effective for treating psoriasis 
than TNF inhibitors [2]. 
 
Case Synopsis 
A 35-year-old man was started on secukinumab for 
chronic plaque psoriasis. Secukinumab replaced 
cyclosporine, administered at a daily dose of 3mg/kg, 
which controlled the patient’s psoriasis insufficiently 
and caused hypertension. Before the initiation of 
secukinumab, the patient’s psoriasis area and 
severity index (PASI) was 4, including psoriasis on 
hands (Figure 1). The patient had a complex history 
of plaque psoriasis and his further previous systemic 
treatments included acitretin, methotrexate, 
etanercept, and adalimumab. He developed a 
biopsy-proven TNF inhibitor induced pulmonary 
sarcoid-like reaction with significant clinical 
symptoms and therefore, this drug class was 
contraindicated. The patient’s other medical history 
included atopy with previous allergic rhinitis but no 
atopic dermatitis. Laboratory analyses underscored  
Abstract 
With a prevalence of up to 20%, eczematous lesions 
are the most common skin adverse events of tumor 
necrosis factor alpha inhibitors. Eczematous lesions 
triggered by more modern biologics such as the 
IL17A antagonist secukinumab have been rarely 
reported. Herein, a case of secukinumab-induced 
pompholyx in a psoriasis patient is presented. 
 
Figure 1. Psoriatic lesions on A, B) both dorsum of hands, and C, D) palms prior to treatment with secukinumab. 
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the atopy of the patient with an elevated grass-
specific IgE (15.20kUA/L). 
The patient had been treated with 300mg 
secukinumab at weeks 0, 1, 2, 3, and 4, followed by 
300mg every four weeks, which resulted in rapid 
remission of the psoriatic plaques. On three-month 
follow-up, the patient reached PASI 100 but 
presented with a new itchy vesicular rash on both 
hands (Figure 2). The patient continued his office job 
and denied contact with new chemicals or relevant 
lifestyle changes. Pompholyx was diagnosed and 
topical treatment with clobetasol propionate 0.05% 
cream was initiated, along with the continuation of 
secukinumab. At six-month follow-up, the patient’s 
pompholyx was well manageable with bi-weekly 
clobetasol propionate 0.05% cream application. 
 
Case Discussion 
It is believed that TNF inhibitors reduce Th1 
mediated immune mechanisms and thereby, switch 
immune responses to a more Th2 dominated 
reactivity prevailing in atopic dermatitis [1]. IL17 
inhibitors impact the Th1 pathway and therefore 
could have a similar effect [2]. A personal history of 
atopy is an established risk factor of developing 
dermatitis during TNF inhibitor therapy [1]. 
The herein presented patient was treated with 
cyclosporine, used for both psoriasis and atopic 
dermatitis, before the initiation of secukinumab. The 
fact that the patient never had dermatitis before 
commencement of cyclosporine argues for 
secukinumab-induced pompholyx and against pre-
existing pompholyx, unmasked by cyclosporine 
cessation. Blackcloud et al. recently described a case 
of bullous acral eruption related to secukinumab, 
which was considered a hypersensitivity reaction 
rather than pompholyx [5]. 
Both IL17A inhibitors, secukinumab and ixekizumab, 
were associated with the onset of dermatitis of the 
face, with a predilection for periocular skin in all 
described patients [3, 4]. On the other hand, 
increased levels of IL17A in the peripheral blood of 
patients with atopic dermatitis were found and a 
phase II placebo-controlled randomized control trial 
is being conducted assessing the efficacy and safety 
of secukinumab for adults with atopic dermatitis [6]. 
 
Conclusion 
Whereas it remains to be seen whether secukinumab 
will play a role as a therapeutic agent in atopic 
dermatitis, the presented case shows that 
secukinumab can be associated with development 
of pompholyx in a predisposed patient. 
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Figure 2. Eczematous lesions on A) the dorsum of the right hand, 
and B) vesicles on the right fifth finger three months after 
secukinumab initiation. 
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